Navigation Links
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
Date:6/1/2008

macodynamic studies in mice, oral administration of XL184 resulted in balanced and durable inhibition of these targets. The compound has also shown activity against common mutant forms of RET and MET. XL184 has exhibited dose-dependent tumor growth inhibition and tumor regression in a variety of tumor models, including breast cancer, colon cancer, MTC, non-small cell lung cancer, and glioblastoma. A pivotal phase 3 trial of XL184 in patients with MTC is planned to begin in the summer of 2008. Phase 1/2 and 2 studies of XL184 in non-small cell lung cancer and glioblastoma multiforme are ongoing.

About Medullary Thyroid Cancer

The American Cancer Society estimates that MTC accounts for 5% of all thyroid cancers. MTC occurs in sporadic and inherited forms (approximately 80% and 20% of MTC, respectively), and is frequently associated with genetic activation of RET. The inherited form usually appears at a younger age, while dietary iodine deficiency and radiation exposure are risk factors for the sporadic form. MTC may metastasize to lymph nodes or other organs before it is ever diagnosed. Additionally, MTC does not take up radioactive iodine, which is commonly used to treat other types of thyroid cancers and to diagnose metastases. As a result, MTC is more difficult to treat than other thyroid cancers. There are no approved therapies for MTC; however, common treatments for MTC include surgery to remove malignant tissue, radiation therapy, and chemotherapy, all of which are associated with potential side effects, some of which may be long-term.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pip
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Exelixis Announces First Quarter 2008 Financial Results
11. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015  BD (Becton, ... leading global medical technology company, today announced its ... Stewardship and outlined multiple steps the company will ... "BD has a full range of expertise ... from diagnosis and treatment information to electronic surveillance ...
(Date:6/2/2015)... Thync today launched the first consumer ... feeling more calm or energized when you need it most. ... simple wearable is placed on the head and designed for ... device is operated with an accompanying app to deliver Thync ... level. "Our mission at Thync is to ...
(Date:6/2/2015)... MADRID , June 2, 2015 ... 10503) effectuée lors de la réunion annuelle de ... PharmaMar communique que Janssen Research & Development, LLC ... multicentrique de phase III SAR3007 qui démontrent une ... avec la trabectédine (YONDELIS ® ) comparé à ...
Breaking Medicine Technology:BD Participates in White House Forum on Antibiotic Stewardship 2BD Participates in White House Forum on Antibiotic Stewardship 3Thync Launches First Wearable to Shift Your State of Mind 2Thync Launches First Wearable to Shift Your State of Mind 3Thync Launches First Wearable to Shift Your State of Mind 4PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 2PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 3PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 4PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 5PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 6
(Date:6/2/2015)... OR (PRWEB) June 02, 2015 With ... dry in most parts of the United States, people ... conditioned rooms. Despite the obvious benefits of air conditioning, ... effects, including dry eye, dehydration and allergic reactions. Fresh ... Hour™ Power of Water® radio show, will discuss the ...
(Date:6/2/2015)... 2015 PhishLine, LLC today announced ... Swenson Drive, Suite 125 in Waukesha, Wisconsin 53186. ... new base of operations for PhishLine’s current corporate ... growth. , Mark Chapman, Founder and President, commented ... as enterprise customers adopt our market leading service ...
(Date:6/2/2015)... Residents of Monarch Landing in Naperville are going to ... do yoga, play volleyball, or participate in whatever their ... Association’s Walk to End Alzheimer’s on September 20 in ... challenge to exercise for 60 days, sponsored by Life ... the walk will raise awareness of Alzheimer’s disease among ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 TranSlice: Reveal from ... new style. TranSlice: Reveal allows Final Cut Pro X users ... lines to reveal their next screen. , TranSlice Reveal brings ... Final Cut Pro X users can now transition ... lines. , With every panel orientation and direction covered, no ...
(Date:6/2/2015)... First Choice Emergency Room , the largest ... States, named Kenneth Alan Totz, D.O.as the new Medical ... , “We are pleased to announce Dr. Totz will ... James M. Muzzarelli, Executive Medical Director of First Choice ... degree from St. Edwards University in Austin, Texas and ...
Breaking Medicine News(10 mins):Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 2Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 3Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 2Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 3Health News:Announcing the release of TranSlice Reveal from Pixel Film Studios - Professional Split Screen Transitions for FCPX. 2Health News:First Choice Emergency Room Announces Dr. Kenneth Alan Totz as New Medical Director of Houston – Jones Road Facility 2
... China, April 13 Sinobiopharma, Inc. (OTC Bulletin Board: ... the sales contracts totaling 1.5 million units for its ... is China,s top-selling pre-surgical skeletal muscle relaxant. , ... exciting time for the company," said Sinobiopharma CEO, Dr. ...
... Group and Henry Ford Health System are ... Workshop" on April 16, 2009 at the Ramada Plaza, ... locals about autism spectrum disorder and developmental disabilities. Parents, ... opportunity to hear from several local experts on a ...
... nuts, and ,Mediterranean, fare most beneficial, researchers find ... nuts and the so-called "Mediterranean" diet are heart-friendly, ... glycemic index can harm your heart, say researchers ... 2007. , The studies included 146 prospective ...
... of antidepressants makes little difference, study finds , , MONDAY, ... that people with heart disease caused by blockage of ... finds. , That finding was to be expected, said ... in Murray, Utah, and lead author of the study, ...
... IT FundingCHICAGO, April 13 Critical care patients ... less likely now to develop complications and have ... health system implemented an advanced information technology system. ... 2006-2008 at 13 Resurrection ICUs, presented last week ...
... a view of nationalized health care - Tuesday, April 14 at ... Reports" takes a look into the state of universal health care ... that has been in place in that country since 1984. ... - from the health care system north of our border as ...
Cached Medicine News:Health News:Sinobiopharma, Inc. Signs Sales Contract for Flagship Project 2Health News:Metro Parent's Second Annual 'Living With Autism Workshop' Features Local Experts Who Are Intimately Involved in Improving the Lives of These Special Children 2Health News:Review Confirms Links Between Diet, Heart Health 2Health News:Heart Disease and Depression Up Heart Failure Risk 2Health News:Resurrection Health Uses Information Technology to Address Critical Care Crisis 2Health News:HDNet's 'Dan Rather Reports' Investigates the Possibility of a Better Health Care System North of the Border 2Health News:HDNet's 'Dan Rather Reports' Investigates the Possibility of a Better Health Care System North of the Border 3
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... Biosoft plus Neu ... spectrum anti-infective alcohol hand ... added ingredients of the ... has been clinically proven ...
... of waterless alcohol hand sanitizers like Aplicare ... soap and water as the recommended product ... 2002 CDC Draft Guidelines for hand hygiene., ... associated infections can be prevented with better ...
Hand antisepsis plays a significant role in preventing nosocomial infections and the associated morbidity, mortality and costs. 3M offers healthcare providers effective hand antisepsis products that ...
Medicine Products: